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Abstract objective Unlike other herpes viruses, Kaposi’s sarcoma-associated herpes virus (KSHV) is not
ubiquitous worldwide and is most prevalent in sub-Saharan Africa. The reasons for this are unclear. As
part of a wider investigation of factors that facilitate transmission in Uganda, a high prevalence
country, we examined the association between antimalaria antibodies and seropositivity against KSHV.
methods Antibodies against P. falciparum merozoite surface protein (PfMSP)-1, P. falciparum
apical membrane antigen (PfAMA)-1 and KSHV antigens (ORF73 and K8.1) were measured in
samples from 1164 mothers and 1227 children.
results Kaposi’s sarcoma-associated herpes virus seroprevalence was 69% among mothers and
15% children. Among mothers, KSHV seroprevalence increased with malaria antibody titres: from
60% to 82% and from 54% to 77%, comparing those with the lowest and highest titres for PfMSP-
1 and PfAMA-1, respectively (P < 0.0001). Among children, only antibodies to PfAMA-1 were
significantly associated with KSHV seropositivity, (P < 0.0001). In both mothers and children, anti-
ORF73 antibodies were more strongly associated with malaria antibodies than anti-K8.1 antibodies.
conclusion The association between malaria exposure and KSHV seropositivity suggests that
malaria is a cofactor for KSHV infection or reactivation.
keywords Kaposi’s sarcoma-associated herpes virus, malaria, Uganda
Introduction
Kaposi’s sarcoma-associated herpes virus (KSHV) is the
causative agent of Kaposi’s sarcoma (KS) [1, 2]. In gen-
eral, the distribution of KSHV mirrors the distribution of
KS [3]. Unlike other herpes viruses that are ubiquitous in
human populations, KSHV and KS demonstrate substan-
tial geographical variation worldwide [4]. The prevalence
of KSHV is highest in sub-Saharan Africa, followed by
the Mediterranean countries, and prevalence is lowest in
Northern European and Asian countries [5]. The princi-
pal modes of transmission of KSHV may also differ
between geographical locations [6]. In sub-Saharan
Africa, KSHV transmission occurs through saliva
throughout life, but particularly in childhood [3]. In low
prevalence settings transmission mainly occurs later in
life, perhaps through sexual contact [3].
As all other known human herpes viruses are ubiqui-
tous worldwide, the geographic variation in prevalence of
KSHV is anomalous and the factors that sustain higher
rates of transmission in sub-Saharan Africa than else-
where are unclear. In a cross-sectional study of women,
hookworm infection, Mansonella perstans and malaria
parasitaemia were independently associated with KSHV
seropositivity; in children, only malaria parasitaemia
showed an association with KSHV seropositivity, but
prevalence of the other parasites was very low [7, 8].
Helminths skew the immune response to a Th2 response
and cause immunosuppression [9, 10]; this immunosup-
pression could lead to loss of viral control and could
consequently cause viral replication. Malaria infection
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impairs the T-cell immune response and causes polyclonal
activation of B cells [11, 12]. Both malaria and helminth
infections could lead to KSHV reactivation in co-infected
individuals.
Repeated malaria exposure has detrimental effects on
immune function [13–16]. These could lead to loss of
immune surveillance of KSHV latently infected cells, con-
sequently causing viral reactivation and replication. The
effect of intense malaria exposure on EBV reactivation (a
related gamma herpesvirus) has been investigated, and it
was shown that exposure to malaria facilitates EBV
transmission [17]. Individuals in areas with high malaria
transmission in Kenya were more likely to be EBV sero-
positive and were at higher risk of Burkitt’s lymphoma
than individuals in areas with low malaria transmission
in Kenya [17, 18]. Together, this suggests that malaria
impacts not just transmission of EBV, but also the
immune response to infection; the same may be true in
relation to KSHV and KS. The purpose of this study was
to investigate the effect of malaria exposure, determined
by measurement of antimalaria antibodies, on KSHV
seropositivity in Ugandan mothers and their children.
Methods
Study design and population
This was a cross-sectional study carried out within the
context of a clinical trial, the Entebbe Mother and Baby
study (EMaBS) (ISRCTN32849447). EMaBS is an ongo-
ing birth cohort that originated as a double-blind, rando-
mised placebo-controlled trial designed to determine the
impact of helminth infections and their treatment on vac-
cine responses and infectious diseases outcomes; the
details have been reported elsewhere [19, 20]. A total of
2507 pregnant women from Entebbe, Uganda, who con-
sented, were recruited into EMaBS and they have been
followed, with their children, for 10 years.
Ethical approval
This study was approved by the Science and Ethics Com-
mittee (SEC) of the Uganda Virus Research Institute,
Uganda National Council for Science and Technology
and the London School of Hygiene & Tropical Medicine
Research Ethics Committee.
KSHV Serology
Stored plasma samples taken from 1164 mothers in the
early post-partum period, and from 1227 of their 5-year
old children, were screened for the presence of KSHV
antibodies using an enzyme-linked immunosorbent assay
(ELISA) for recombinant proteins to a lytic structural gly-
coprotein, K8.1 and a latent nuclear protein latency-asso-
ciated nuclear antigen (LANA) encoded by ORF73. Each
plate contained three positive and three negative controls.
Each assay cut-off was calculated based on the perfor-
mance of the negative controls. This procedure has been
reported elsewhere [21, 22].
Malaria serology
The same plasma samples were tested for malaria antibod-
ies using two P. falciparum antigens: merozoite surface
protein (MSP)-1 and apical membrane antigen (AMA)-1
[23]. A pool of malaria positive plasma samples from
patients known to be infected with malaria was used to
make standard dilutions. This pool was diluted serially five
times starting from 1:50 for MSP-1 and 1:100 for AMA-1
to make six standards with a fourfold dilution increment.
Optical densities (ODs) obtained were then exported into
Microsoft Excel, and antibody titres for each sample and
each antigen were derived from the standard curve, of
ODs. Blank wells were used to subtract background absor-
bance from the standards and the samples. This procedure
has been reported elsewhere [24].
Statistical analysis
Statistical analysis was performed using Stata-12 software
(STATA 12.1, Statacorp, College Station, USA). Sepa-
rately for mothers and children, odds ratios (ORs) and
95% confidence intervals (CIs) were calculated using the
Mantel–Haenszel test and logistic regression to obtain
crude and adjusted odds ratios and P-values; all P-values
are two-sided. To determine the effect of malaria antibod-
ies on KSHV seropositivity, we grouped malaria antibody
titres into three groups, for mothers and children sepa-
rately: low, middle and high. The selection of the groups
was not based on any biological or clinical criteria but on
the frequency distribution of the titres. Antibody titres
from below the 25th quartile were grouped as low, from
the 25th to 75th quartile as middle and above the 75th
quartile as high. As grouping continuous risk factors leads
to loss of information [25], we also analysed the effect of
malaria antibody titres as a continuous variable.
Results
To determine the level of malaria exposure, we quantified
antibody titres to Plasmodium falciparum malaria using
two antigens, PfMSP-1 and PfAMA-1. As expected, anti-
body titres to both PfMSP-1 and PfAMA-1 were much
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higher in mothers compared to children. The median
antibody titres to PfMSP-1 and PfAMA-1 among mothers
were 737.5 and 600.2, respectively, while the median
antibody titres to PfMSP-1 and PfAMA-1 among chil-
dren were 103.4 and 17.2, respectively. To establish the
seroprevalence of KSHV among mothers and their chil-
dren, we tested for KSHV-specific antibodies using two
KSHV antigens, K8.1 and ORF73. Individuals with anti-
bodies to either ORF73 or K8.1 were considered to be
KSHV seropositive, and individuals with antibodies to
neither ORF73 nor K8.1 were considered to be KSHV
seronegative. The seroprevalence of KSHV was 69%
(806/1164) among mothers and 15% (185/1227) among
children. Among mothers, 64% (744) were positive for
anti-ORF73 antibodies and 46% (539) were positive for
anti-K8.1 antibodies. Among children, 8% (96) were
positive for anti-ORF73 antibodies and 12% (148) were
positive for anti-K8.1 antibodies.
Tables 1 and 2 show crude and adjusted associations
between KSHV seropositivity, socio-demographic factors
and other clinical factors among mothers and children,
respectively. Household socioeconomic status and loca-
tion were independently associated with KSHV seropos-
itivity both in the mothers and in the children [7, 8].
Age was crudely associated with KSHV seropositivity
(P = 0.01) among mothers, but the association was lost
when we adjusted for household socio-economic status
and location. Because all children were 5 years old, age
was not included in the analysis of children’s data.
Among mothers, malaria antibodies to both PfMSP-
1and PfAMA-1 were strongly associated with KSHV
seropositivity. The odds of being KSHV seropositive
Table 1 Prevalence of KSHV among women. Crude and adjusted associations with KSHV serostatus and socio-demographics and
some clinical factors among 1164 mothers
Risk factor
Prevalence of KSHV
among women
Crude odds ratio
(95% CI) P
Adjusted odds ratios
(95% CI) P
Age group
14–19 75% (212/282) 1 0.01 (trend) 1 0.07 (trend)
20–24 69% (299/433) 0.74 (0.53–1.03) 0.75 (0.53–1.06)
25–29 66% (175/265) 0.64 (0.44–0.93) 0.70 (0.47–1.02)
30+ 65% (120/184) 0.62 (0.41–0.93) 0.68 (0.44–1.03)
Household SES
1 (lowest) 82% (49/60) 1 <0.0001 (trend) 1 <0.0001 (trend)
2 75% (77/103) 0.66 (0.30–1.47) 0.70 (0.31–1.55)
3 72% (254/350) 0.59 (0.30–1.19) 0.56 (0.78–1.13)
4 68% (228/335) 0.48 (0.24–0.96) 0.46 (0.23–0.93)
5 65% (145/224) 0.41 (0.20–0.84) 0.43 (0.21–0.88)
6 (highest) 49% (33/67) 0.22 (0.10–0.49) 0.22 (0.10–0.49)
Location
Urban* 65% (286/439) 1 0.002 (trend) 1 0.002 (trend)
Peri-urban† 70% (309/444) 1.22 (0.92–1.62) 1.26 (0.94–1.69)
Rural‡ 76% (206/271) 1.70 (1.21–2.38) 1.77 (1.24–2.52)
Tribe
Buganda 70% (419/601) 1 0.7
Other tribes§ 69% (386/562) 0.95 (0.74–1.22)
HIV seronegative 69% (694/1004) 1 0.8
HIV seropositive 70% (112/160) 1.04 (0.72–1.50)
Anaemia
No 67% (472/699) 1 0.1
Yes 72% (334/465) 1.23 (0.95–1.59)
SES (socio-economic status), CI (confidence interval). KSHV seropositive is defined as seropositive to either ORF73, and/or K8.1. A
composite variable for household socio-economic status was derived based on home building materials, number of room and items col-
lectively owned.
Adjusted odds ratios were adjusted for age group, household socio-economic status and location.
*Urban is Entebbe area.
†Peri-urban are Kigungu and Manyago areas.
‡Rural are Katabi road side and Katabi far from the road areas.
§Other tribes include Banyankole, Batoro, Basoga, Luo, Banyarwanda and any other tribes.
Bold values are statistically significant
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among mothers with high malaria antibody titres, com-
pared to those with low malaria antibody titres, were
2.67 (P < 0.0001) and 2.43 (P < 0.0001) for PfMSP-1
and PfAMA-1 antibodies, respectively (Table 3). Among
children, malaria antibodies to PfAMA-1 were strongly
associated with KSHV seropositivity. The odds of being
KSHV seropositive among children with high PfAMA-1
antibody titres, compared to those with low PfAMA-1
antibody titres, were 1.59 (P = 0.02) (Table 4). PfMSP-1
antibody titres were not significantly associated with
KSHV seropositivity among children (Table 4).
We also analysed antibodies to ORF73 and K8.1 sep-
arately. Among mothers, the association between
malaria antibodies and the presence of ORF73 seroposi-
tivity was stronger than the association between
malaria antibodies and K8.1 seropositivity (Table 5).
Findings among children were similar (Table 6),
although mothers had a stronger association between
malaria antibodies and KSHV seropositivity (compare
Tables 5 and 6).
Treating antimalaria antibody titres as a continuous
variable, among mothers, for every fourfold increase in
malaria antibody titre, the odds of being KSHV seroposi-
tive increased by 67% (P < 0.0001) for PfMSP-1 anti-
body titres and 60% (P < 0.0001) for PfAMA-1
antibody titres. In the children, for every fourfold
increase in PfAMA-1 antibody titres, the odds of being
KSHV seropositive increased by 53% (P < 0.0001).
PfMSP-1 antibody titres were not associated with KSHV
seropositivity among children.
Discussion
To our knowledge, this is the first study to investigate
malaria antibodies in relation to KSHV seropositivity. Its
major findings are as follows: (1) KSHV seropositivity
Table 2 Prevalence of KSHV among five-year-old children. Crude and adjusted associations with KSHV serostatus and socio-demo-
graphic factors among 1227 children
Risk factor
Prevalence of KSHV
among children
Crude odds ratio
(95% CI) P
Adjusted odds ratios
(95% CI) P
Household SES
1 (lowest) 23% (16/71) 1 0.05 (trend) 1 0.04 (trend)
2 18% (14/81) 0.72 (0.32–1.60) 0.75 (0.33–1.68)
3 16% (60/368) 0.67 (0.36–1.25) 0.65 (0.35–1.22)
4 12% (43/352) 0.48 (0.25–0.91) 0.46 (0.24–0.88)
5 15% (38/255) 0.61 (0.31–1.16) 0.57 (0.30–1.11)
6 (highest) 12% (9/78) 0.45 (0.18–1.09) 0.44 (0.18–1.08)
Location
Urban* 14% (64/463) 1 0.01 (trend) 1 0.01 (trend)
Peri-Urban† 13% (65/498) 0.94 (0.65–1.36) 0.88 (0.6–1.29)
Rural‡ 22% (56/255) 1.75 (1.18–2.61) 1.80 (1.20–2.69)
Maternal age group
14–19 13% (33/253) 1 0.3 (trend)
20–24 16% (76/473) 1.28 (0.82–1.98)
25–29 13% (38/294) 0.99 (0.60–1.63)
30+ 19% (38/207) 1.50 (0.90–2.49)
Sex
Boys 16% (101/626) 1 0.3
Girls 14% (84/601) 0.84 (0.62–1.15)
Tribe
Buganda 15% (103/683) 1 0.9
Other tribes§ 15% (82/544) 0.99 (0.73–1.37)
SES (socio-economic status), CI (confidence interval) KSHV seropositive is defined as seropositive to either ORF73 and/or K8.1. A com-
posite variable for household socio-economic status was derived based on home building materials, number of room and items collec-
tively owned.
Adjusted odds ratios adjusted for household socio-economic status and location.
*Urban is Entebbe area.
†Peri-urban are Kigungu and Manyago areas.
‡Rural are Katabi road side and Katabi far from the road areas.
§Other tribes include Banyankole, Batoro, Basoga, Luo, Banyarwanda and any other tribe.
Bold values are statistically significant
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was strongly associated with malaria antibodies to both
PfMSP-1 and PfAMA-1 in the mothers. (2) In the chil-
dren, KSHV seropositivity was highly associated with
malaria antibody titres to PfAMA-1 but not PfMSP-1.
(3) In both mothers and their children, the association
between malaria antibodies and KSHV antibodies was
much stronger with ORF73 antibodies than K8.1 anti-
bodies.
Kaposi’s sarcoma-associated herpes virus seropositivity
was strongly associated with both malaria antibodies in
the mothers. In this study, we have used malaria antibod-
ies as a proxy measure of malaria exposure. Continuous
exposure to malaria infection leads to the development of
an antibody response, some of which is associated with
protective immunity to clinical disease [26–28]. The exact
correlates of protection for malaria are unknown,
although high malaria antibody titres to the malarial
antigens used here (MSP-1 and AMA-1) have been associ-
ated with protection in some studies [26, 29–31]and
have, more recently, been used to demonstrate cumulative
exposure with age to classify areas of different malaria
endemicity [32, 33]. Therefore, malaria antibody titres
correlate with malaria infection exposure. Repeated expo-
sure to malaria infection has been associated with detri-
mental effects on immune function [14, 16] such as
T- and B-cell exhaustion [13] and impairment of myeloid
lineage cells such as dendritic cells function [15]. During
KSHV latent infection, the immune system, through the
action of cytotoxic T lymphocytes, prevents viral replica-
tion and hence keeps the virus in latency. The loss of
Table 3 Association of antimalaria antibodies with prevalence of KSHV among women. Crude and adjusted associations between
KSHV serostatus and malaria antibody titres among 1164 mothers
Risk factor
Prevalence of KSHV
among women
Crude odds ratio
(95% CI) P
Adjusted odds ratio
(95%CI) P*
PfMSP-1 titres
Lowest 60% (174/292) 1 <0.0001 1 <0.0001
Middle 68% (394/581) 1.43 (1.07–1.91) 1.47 (1.07–2.03)
Highest 82% (238/291) 3.05 (2.09–4.45) 2.67 (1.77–4.04)
PfAMA-1 titres
Lowest 54% (158/293) 1 <0.0001 1 <0.0001
Middle 73% (423/580) 2.30 (1.72–3.09) 2.08 (1.5–2.87)
Highest 77% (225/291) 2.91 (2.04–4.17) 2.43 (1.63–3.62)
*Adjusted odds ratios were adjusted for hookworm infection, Mansonella perstans infection, socio-demographic factors (age group,
household socio-economic status, location) and HIV status. PfMSP-1 (Plasmodium falciparum merozoite surface protein-1), PfAMA-1
(Plasmodium falciparum apical membrane antigen-1), CI (confidence interval) PfMSP-1 and PfAMA-1 antibody titres were analysed
using separate regression models. KSHV seropositive is defined as seropositive to either ORF73 and/or K8.1.
Bold values are statistically significant
Table 4 Association of antimalaria antibodies with prevalence of KSHV among children. Crude and adjusted associations between
KSHV serostatus and malaria antibody titres among 1227 children
Risk factor
Prevalence of KSHV
among children
Crude odds ratios
(95% CI) P
Adjusted odds ratio
(95% CI) P*
PfMSP-1 titres
Lowest 14% (42/307) 1 0.2 1 0.4
Middle 15% (89/614) 1.07 (0.72–1.59) 1.05 (0.70–1.56)
Highest 18% (54/306) 1.35 (0.87–2.10) 1.23 (0.79–1.92)
PfAMA-1 titres
Lowest 14% (43/313) 1 0.002 1 0.02
Middle 12% (73/608) 0.86 (0.57–1.28) 0.84 (0.56–1.26)
Highest 23% (69/306) 1.83 (1.20–2.78) 1.59 (1.03–2.45)
*Adjusted odds ratios were adjusted for socio-demographic factors (sex, household socio-economic status and location). PfMSP-1 (Plas-
modium falciparum merozoite surface protein-1), PfAMA-1 (Plasmodium falciparum apical membrane antigen-1) CI (confidence inter-
val). PfMSP-1 and PfAMA-1 antibody titres were analysed using separate regression models. KSHV seropositive is defined as
seropositive to either ORF73 and/or K8.1.
Bold values are statistically significant
© 2015 The Authors. Tropical Medicine & International Health published by John Wiley & Sons Ltd. 669
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T-cell immunity during repeated malaria infections could
lead to loss of viral control and could consequently lead
to KSHV transmission as a result of viral replication; (2)
and/or render KSHV-negative individuals more suscepti-
ble to the infection, hence leading to KSHV acquisition.
The association between KSHV seropositivity and
malaria antibodies could also be directly due to the
effects of malaria parasite infection. We have previously
shown that asymptomatic malaria parasitaemia is associ-
ated with KSHV seropositivity [7, 8]. Possible mecha-
nisms through which malaria infection could impact
KSHV replication are (i) immunosuppression and (ii)
polyclonal activation of KSHV latently infected B cells;
malaria parasites cause both.
We found that, in both mothers and their children, the
association between KSHV antibodies and malaria anti-
bodies is much stronger with ORF73 antibodies than
with K8.1 antibodies. ORF73 encodes LANA (latently
associated nuclear antigen), which is expressed during
latency to facilitate KSHV episomal replication, segrega-
tion of the KSHV genomes to daughter cells and viral
oncogenicity [34]. K8.1, in contrast, is a structural pro-
tein expressed during lytic replication. There are a num-
ber of possible mechanisms that may explain this;
however, there is considerable heterogeneity in the anti-
body response to more than 85 KSHV antigens [22]. Fur-
ther studies are needed to understand the interaction of
KSHV antigens with the immune system.
Unlike in the mothers, we observed that KSHV sero-
positivity is associated with antibodies to PfAMA-1 but
not PfMSP-1 in the children. Possible explanations (either
alone or in combination) could be that (i) the KSHV se-
roprevalence was very low in children (15%); this might
have hindered detection of significant associations. (ii)
The PfAMA-1 used is a larger molecule, will have more
epitopes and therefore, is potentially a more sensitive bio-
marker for exposure [35]. Also, antibodies to PfMSP-1
take longer to develop, and hence their levels during early
life are less well correlated with malaria exposure [29].
Our sample sizes were large enough to allow detection
of statistically significant associations, at least in the
mothers. Also, data on possible confounders were avail-
able; therefore, we were able to adjust for them. We were
also able to detect specific antibody responses to more
than one antigen per infection. Potential weaknesses were
the lack of any information on the temporality, which
could have effects on malaria infection distribution, and
the cross-sectional study design, which did not allow us
to ascertain when malaria antibody titres increased and
when KSHV primary infection occurred.
Repeated exposure to malaria infection has detrimental
effects on immune function, for example by leading to B-
and T-cell exhaustion. We have shown that exposure to
malaria infection, detected using malaria antibodies, is
highly associated with KSHV seropositivity. Therefore, it
is possible that malaria exposure is facilitating reactiva-
tion of KSHV, and perhaps also increasing the suscepti-
bility to infection, which in turn may lead to increased
transmission.
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